A Study of Isoprinosine in Patients With Severe AIDS
Launched by NEWPORT PHARMACEUTICALS INTERNATIONAL · Aug 30, 2001
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Exclusion Criteria
- Co-existing Condition:
- • Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer are excluded.
- Concurrent Medication:
- Excluded:
- • Steroids.
- • Cytotoxic immunosuppressive agents.
- • Radiotherapy.
- The following are excluded:
- • Critically ill patients.
- • Patients receiving steroids, cytotoxic immunosuppressive agents, radiotherapy.
- • Patients who have received any other immunotherapy.
- • Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer.
- Prior Medication:
- Excluded:
- • Any other immunotherapy.
- • Patients with severe AIDS and specified laboratory immunologic defects.
About Newport Pharmaceuticals International
Newport Pharmaceuticals International is a leading biopharmaceutical company dedicated to advancing innovative therapies that address unmet medical needs across various therapeutic areas. With a strong focus on research and development, Newport Pharmaceuticals harnesses cutting-edge science and technology to create effective treatments aimed at improving patient outcomes. The company is committed to conducting rigorous clinical trials that adhere to the highest ethical standards, ensuring safety and efficacy while fostering collaboration with healthcare professionals and regulatory bodies. Through its dedication to innovation and excellence, Newport Pharmaceuticals International strives to make a meaningful impact on global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Laguna Hills, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials